7 results
The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week (eow) subcutaneously (SC) starting at Week 1 compared with placebo in subjects with inactive non-…
Primary Objective* To assess the safety, tolerability, and efficacy (in terms of change in DAS28 [using C-ReactiveProtein (CRP)] from baseline) of JNJ-38518168 at a dose of 100 mg/day for up to 12 weekscompared to placebo in subjects with active…
The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week (eow) subcutaneously (SC) starting at Week 1 compared with placebo as maintenance therapy in subjects…
To evaluate the effectiveness and safety of concentration controlled combination of once daily dosed low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus (trough levels:3-5 ng/ml), in order to provide superior renal function…
To determine the safety of the MobiusHD System and the efficacy of the MobiusHD device in lowering mean systolic 24-hour ambulatory blood pressure in subjects with resistant hypertension. The hypothesis is that mean systolic 24-hour ambulatory blood…
To determine the safety of the MobiusHD System and the efficacy of the MobiusHD device in lowering mean systolic 24-hour ambulatory blood pressure in subjects with resistant hypertension. The hypothesis is that mean systolic 24-hour ambulatory blood…
To compare pembrolizumab plus docetaxel plus prednisone to placebo plus docetaxel plus prednisone with respect to overall survival (OS)